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Abstract 
Aurora family of protein kinases have emerged as crucial factors of, not only mitosis and 
cytokinesis, but also human carcinogenesis. Among these family members is Aurora-A that is 
frequently overexpressed in varieties of human cancer. Both in vitro and in vivo studies 
demonstrated that Aurora-A induces tumorigenesis through genome instability. These 
studies have further shown that cell signaling cross-talk between Aurora-A and other cellular 
proteins are essential for fully-transformed phenotypes. This review summarizes recent 
progress of Aurora-A-associated carcinogenesis.   
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Introduction 
Aurora-A was discovered in a screen for Dro-
sophila mutations affecting the poles of the mitotic 
spindle function [1]. Transcription of the Aurora-A 
gene is cell-cycle regulated. Thus, the promoters of the 
Aurora-A gene contain specific elements (CDE/CHR 
sequences), which are responsible for transcription at 
G2 phase of the cell cycle [2-4]. It has been well 
documented that activation of Aurora-A is required 
for mitotic entry, centrosome maturation and separa-
tion, and G2 to M transition [5.6]. Interestingly, over-
expression of Aurora-A is frequently observed in va-
rieties of human cancer, including breast, colorectal, 
bladder, pancreatic, gastric, ovarian and esophageal 
cancer [7-12]. Overexpression of Aurora-A in fibro-
blasts resulted in cell transformation, supporting a 
notion that high levels of this protein are correlated to 
cell malignancy [13]. 
Potential roles of Aurora-A in cell transforma-
tion were also demonstrated from recent studies that 
this kinase phosphorylates a breast cancer tumor 
suppressor BRCA1 at Ser308 [14]. Both proteins are 
localized on centrosome at the beginning of mitosis 
[15], suggesting that signaling between these two 
proteins are crucial for regulation of normal cell cycle. 
Recent studies added a couple of new insight of 
how Aurora-A induces cell transformation. Thus, in 
physiological conditions, Aurora-A and its activator 
collaborate with Plk1, Polo-like kinase 1, to initiate 
mitosis. On the other hand, in cells transformed with 
Aurora-A, mTOR pathway is activated [16,17]. 
In this review, differential roles of Aurora-A in 
cell cycle and cell transformation are discussed. 
Aurora-A and BRCA1 
The Aurora-A gene locus is located in the 20q13 
chromosome region, which is frequently amplified in 
several different types of malignancies such as breast, 
colorectal, pancreatic, and bladder cancers [7-12]. In 
particular, 20q11-q13 regions are amplified in 40% of 
breast cancer cell lines as well as in 12-18% of primary 
tumors. Aurora-A protein is a member of the Ser/Thr 
kinase family, and recent studies have shown that the 
protein is involved in the G2-M checkpoint and com-
mitment to mitosis [18-21]. Furthermore, it has been 
demonstrated that Aurora-A is inactivated by DNA 
damage at the end of the G2 phase, and overexpres-Int. J. Biol. Sci. 2009, 5 
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sion of Aurora-A abrogates the G2 checkpoint, re-
sulting in the amplified centrosome and cell trans-
formation [18]. Significantly, Aurora-A is recruited to 
the centrosome early in the G2 phase and becomes 
phosphorylated and activated in the centrosome late 
in the G2 phase [6].  
Deng’s lab demonstrated that ~25% of mouse 
embryonic fibroblasts (MEFs) derived from the 
BRCA1 exon 11-deleted mice contains more than two 
centrosomes, leading to loss of the G2-M checkpoint 
and aneuploidy [21]. In addition, we and others found 
that BRCA1 is localized in the centrosome and binds 
to γ-tubulin [15,22,23]. 
From these observations, we discovered that 
BRCA1 functionally interacts with Aurora-A [14]. 
Interestingly, the aa1314-1863 region of BRCA1 was 
found to bind to Aurora-A directly. Mutagenic analy-
sis and phospho-specific antibodies revealed that S308 
of BRCA1 is normally phosphorylated by Aurora-A 
early in the M phase. Phosphorylation of BRCA1 S308 
by Aurora-A was abolished by treating cells with 
ionizing radiation. Most interestingly, re-expression 
of the phospho-deficient form of BRCA1, S308N 
(N=Asn), in BRCA1-mutated MEFs resulted in 
growth arrest at the G2 phase without any cell stress, 
indicating that phosphorylation of BRCA1 S308 is 
necessary for the transition from G2 to M. These re-
sults indicate that an unphosphorylated form of 
BRCA1 at S308 is necessary for G2-M checkpoint. 
These are the first indications of the roles of the 
physiological levels of BRCA1 phosphorylation in 
regulating the cell cycle. Additional evidence of 
BRCA1/Aurora-A interaction is that Aurora-A regu-
lates inhibition of centrosome microtubule nucleation 
mediated by BRCA1’s E3 ligase activity [24]. 
Exogenous overexpression of Aurora-A in hu-
man cell culture was further studied by transfecting 
U2OS osteosarcome cell line [17]. Interestingly, in 
those cells, increased phosphorylation of BRCA1 S308 
was not detected [unpublished results]. These results 
suggest that phosphorylation of BRCA1 S308 may not 
be necessary for cell transformation. Thus, perhaps 
there is substrate selectivity by Aurora-A in physio-
logical and malignant conditions. 
Aurora-A and mTOR   
Most prominent discoveries from 
MMTV-Aurora-A transgenic mice are constitutive 
phosphorylation of mTOR Ser2448 and Akt Ser473 in 
developed mammary tumors [16]. Mammalian target 
of rapamycin (mTOR) is a protein serine/threonine 
kinase that controls a broad range of cellular proc-
esses. mTOR exists in two distinct complexes; mTOR 
complex 1 (mTORC1) and complex 2 (mTORC2). 
mTOR is phosphorylated at multiple sites, including 
Ser2448, Ser2481, Thr2446 and Ser1261. Phosphoryla-
tion at Ser2448 is mediated by p70 ribosomal S6 kinase 
(S6K) and occurs predominantly to mTOR in 
mTORC1 [25-27]. mTORC1 is composed of mTOR, 
mLST8, raptor and PRAS40. Its function is involved in 
many growth-related processes such as translation, 
ribosome biogenesis, transcription, autophagy and 
hypoxic adaptation, and is sensitive to rapamycin. 
mTORC2 shares both mTOR and mLST8 with 
mTORC1. Other unique components in mTORC2 are 
rapamycin-insensitive companion of mTOR (rictor), 
mammalian stress-activated protein 
kinase-interacting protein 1(mSIN1) and proline-rich 
repeat protein-5 (PRR5) or PRR5-like [28-33]. 
Two major functions have been ascribed to 
mTORC2, including regulation of Akt and cell cy-
cle-dependent organization of actin cytoskeleton. 
mTORC2 phosphorylates Akt at Ser473 in its 
C-terminal hydrophobic motif, which, in conjunction 
with PDK1-mediated phosphorylation of Thr308, 
confers full activation of Akt [34]. mTORC2 regulates 
actin cytoskeleton through a mechanism that involves 
the small GTPases Rho and Rac, although the mo-
lecular details are largely still unclear [8,35]. Interest-
ingly, mTORC2 phosphorylates PKC and SGK1 (se-
rum- and glucocorticoid-induced protein kinase 1), 
and has been implicated in controlling cell size 
[36-39].  
Elevated phosphorylation of mTOR Ser2448 and 
Akt Ser473 in Aurora-A transformed cells suggests 
that Aurora-A can potentially regulate two mTOR 
pathways, mTORC1 and mTORC2. Since chemical 
inhibitors of mTOR can abolish transformed pheno-
types induced by Aurora-A [17], it is likely that either 
or both of mTORC1 and 2 is important for Aurora-A 
transformation.  
Of note, mammary tumor development can be 
observed only after long latency in MMTV-Aurora-A 
mice [16]. In cell culture system of stable transfectants, 
cells in early passage numbers do not contain phos-
phorylated mTOR and Akt, but cells after long pas-
sage numbers they show up [17]. As one possible in-
terpretation, overexpression of Aurora-A is not a 
strong driving force, but some additional events need 
to happen to accelerate Aurora-A’s tumor develop-
ment. When mTOR pathway is activated under this 
situation, cells now acquire the full-transforming 
ability.  
Aurora-A and Plk1 
Expression of Plk1 is cell cycle-dependent. Lev-
els of the protein increases in late G2 phase, and de-
creases during mitotic exit [40]. Kinase activity well Int. J. Biol. Sci. 2009, 5 
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correlates with levels of the protein, thus it increases 
at G2/M transition and reaches at the maximal during 
mitosis. Similar to Plk1, levels of Aurora-A increase 
during G2 and reach at the maximal in early mitosis 
[13,41]. ‘Activator’ proteins for Aurora-A have been 
identified. Those include TPX2, Ajuba, PAK1, HEF1 
and hBora [6,42-47]. Among these Aurora-A interac-
tors, hBora expression peaks during G2 and decreases 
rapidly during mitosis [48,49]. It has also been shown 
that hBora forms a complex with Plk1 in G2 phase 
[48,50,51]. Aurora-A’s binding to Bora and its subse-
quent phosphorylation are required for full activation 
of Aurora-A. In addition, both proteins are essential 
for Plk1 activation at the centrosome in G2 phase. In 
this model, it is thought that Bora binding to Plk1 
induces allosteric effects that allow Aurora-A to the 
Plk1 T-loop of its kinase domain, where Aurora-A 
phosphorylates Thr210, leading to full activation of 
Plk1 [51,52].  
It has been speculated that Aurora-A is a target 
for ubiquitination by CHFR, checkpoint with FHA 
and RING finger domains. CHFR regulates an early 
mitotic checkpoint, during prophase, in response to 
the disruption of microtubule formation or stabiliza-
tion as assessed after treatment with microtubule in-
hibitors such as nocodazole, colcemid and taxanes 
[53]. Interestingly, Aurora-A was overexpressed in 
CHFR-null mouse embryonic fibroblasts and tissues, 
strongly supporting that CHFR ubiquitinates 
Aurora-A [54]. These studies have also demonstrated 
that the C-terminal cysteine-rich region of CHFR 
protein interacts with the N-terminus of Aurora-A 
protein. Similar results were shown from the other 
studies that siRNA-mediated depletion of CHFR in 
MCF10A cells resulted in overexpression of Aurora-A 
[55]. It has been demonstrated that, in HCT116 cells 
overexpressing CHFR, there was no change in levels 
of Aurora-A and localization of Aurora-A to the cen-
trosomes, however, nocodazole-induced 
CHFR-mediated mitotic delay was associated with 
unphosphorylation of Aurora-A at Thr288 [56]. 
Studies of CHFR protein further supported 
functional interaction between Aurora-A and Plk1. It 
has been shown that overexpression of CHFR mutants 
which mimic unphosphorylated CHFR can decrease 
levels and kinase activity of Plk1 [57]. Interestingly, 
mouse embryonic fibroblasts from CHFR knockout 
mice express high levels of Plk1, suggesting that 
CHFR can ubiquitinate Plk1 to target it for degrada-
tion [54]. 
CONCLUSION 
Given the high frequency of overexpression of 
Aurora-A in human cancers, inhibition of Aurora-A 
with small compounds looks like an attractive can-
cer-therapeutic strategy. Several compounds have 
been synthesized and are under clinical trials.  
Classical cell biology assay, such as transfection 
of normal fibroblasts with Aurora-A cDNA, resulted 
in cell transformation. Transgenic model targeting 
Aurora-A in mammary glands also support a notion 
that this kinase is oncogenic. However, quite long 
latency and low incidence of tumor development in 
these mice suggest that Aurora-A alone is not a strong 
driving force of malignancy, but other hits need to 
occur for full transformation [16]. Thus, it is possible 
that inhibition of Aurora-A with compounds may not 
be sufficient for killing Aurora cancer cells. Chromo-
some instabilities observed in those mammary tumors 
support this hypothesis that activation or inactivation 
of ‘effector proteins’ due to the gross alteration of 
chromosome structure may result in accelerating tu-
morigenesis (Fig. 1). In that sense, simultaneous inhi-
bition of this pathway(s) as well as Aurora-A might be 
necessary for the better treatment of patients. For 
example, mTOR/Akt pathway might be the one 
which is crucial for Aurora-A tumorigenesis.  
 
 
Figure 1. Model of Aurora-A cell transformation. Physiological regulation of Aurora-A kinase activity is by BRCA1, hBora, 
Ajuba, TPX2 an dPlk1 etc, however, cell transformation by Aurora-A requires additional oncogenic events, such as con-
stitutive activation of mTOR/Akt pathway and loss of PTEN tumor suppressor [17]. Int. J. Biol. Sci. 2009, 5 
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